{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:05:59Z","timestamp":1787504759085,"version":"build-2736575974"},"reference-count":20,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T00:00:00Z","timestamp":1535068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP16mk0101017j0103"],"award-info":[{"award-number":["JP16mk0101017j0103"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Pharm Ther"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1111\/jcpt.12753","type":"journal-article","created":{"date-parts":[[2018,8,25]],"date-time":"2018-08-25T00:54:07Z","timestamp":1535158447000},"page":"62-68","source":"Crossref","is-referenced-by-count":12,"title":["Identification of risk factors and development of detection algorithm for denosumab-induced hypocalcaemia"],"prefix":"10.1155","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8160-7335","authenticated-orcid":false,"given":"Takuya","family":"Imatoh","sequence":"first","affiliation":[{"name":"Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimie","family":"Sai","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayu","family":"Takeyama","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan"},{"name":"Graduate School of Pharmaceutical Sciences; Tohoku University; Sendai Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhito","family":"Hori","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy; School of Medicine; Hamamatsu University; Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Karayama","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology; School of Medicine; Hamamatsu University; Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine; School of Medicine; Hamamatsu University; Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Segawa","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michio","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Medical Informatics; School of Medicine; Hamamatsu University; Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy; School of Medicine; Hamamatsu University; Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Medicinal Safety Science; National Institute of Health Sciences; Kawasaki Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,8,24]]},"reference":[{"key":"10.1111\/jcpt.12753-BIB0001|jcpt12753-cit-0001","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.critrevonc.2005.03.011","article-title":"Management of bone metastases in cancer: a review","volume":"56","author":"Selvaggi","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1111\/jcpt.12753-BIB0002|jcpt12753-cit-0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1111\/jcpt.12753-BIB0003|jcpt12753-cit-0003","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12753-BIB0004|jcpt12753-cit-0004","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, Double-Blind Study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1111\/jcpt.12753-BIB0005|jcpt12753-cit-0005","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1111\/jcpt.12753-BIB0006|jcpt12753-cit-0006","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1159\/000447372","article-title":"Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta-analysis of randomized controlled trials","volume":"39","author":"Chen","year":"2016","journal-title":"Oncol Res Treat"},{"key":"10.1111\/jcpt.12753-BIB0007|jcpt12753-cit-0007","unstructured":"Dear Healthcare Professional Letter of Rapid Safety Communication (RANMARK SUBCUTANEOUS INJECTION 120\u00a0mg (denosumab) -Risk of severe hypocalcaemia, including fatal cases) 2012 https:\/\/www.pmda.go.jp\/files\/000153380.pdf#search=%27https%3A%2F%2Fwww.pmda.go.jp%2Ffiles%2F000153380.pdf%27"},{"key":"10.1111\/jcpt.12753-BIB0008|jcpt12753-cit-0008","doi-asserted-by":"crossref","first-page":"131","DOI":"10.3414\/ME10-01-0015","article-title":"SS-MIX: a ministry project to promote standardized healthcare information exchange","volume":"50","author":"Kimura","year":"2011","journal-title":"Methods Inf Med"},{"key":"10.1111\/jcpt.12753-BIB0009|jcpt12753-cit-0009","doi-asserted-by":"crossref","first-page":"560","DOI":"10.3414\/ME9125","article-title":"High speed clinical data retrieval system with event time sequence feature: with 10\u00a0years of clinical data of Hamamatsu University Hospital CPOE","volume":"47","author":"Kimura","year":"2008","journal-title":"Methods Inf Med"},{"key":"10.1111\/jcpt.12753-BIB0010|jcpt12753-cit-0010","unstructured":"The Japan Endocrine Society The Guide for the Differential Diagnosis of Hypocalcemia"},{"key":"10.1111\/jcpt.12753-BIB0011|jcpt12753-cit-0011","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/bmj.4.5893.643","article-title":"Interpretation of serum calcium in patients with abnormal serum proteins","volume":"4","author":"Payne","year":"1973","journal-title":"Br Med J"},{"key":"10.1111\/jcpt.12753-BIB0012|jcpt12753-cit-0012","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"key":"10.1111\/jcpt.12753-BIB0013|jcpt12753-cit-0013","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1016\/j.ejca.2015.05.016","article-title":"Hypocalcaemia in patients with metastatic bone disease treated with denosumab","volume":"51","author":"Body","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1111\/jcpt.12753-BIB0014|jcpt12753-cit-0014","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1002\/pds.4045","article-title":"Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting","volume":"25","author":"Huynh","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1111\/jcpt.12753-BIB0015|jcpt12753-cit-0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1507\/endocrj.EJ16-0003","article-title":"High serum ALP level is associated with increased risk of denosumab-related hypocalcemia in patients with bone metastases from solid tumors","volume":"63","author":"Kinoshita","year":"2016","journal-title":"Endocr J"},{"key":"10.1111\/jcpt.12753-BIB0016|jcpt12753-cit-0016","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1248\/bpb.b13-00496","article-title":"Identification of the risk factors associated with hypocalcemia induced by denosumab","volume":"36","author":"Okada","year":"2013","journal-title":"Biol Pharm Bull"},{"key":"10.1111\/jcpt.12753-BIB0017|jcpt12753-cit-0017","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12753-BIB0018|jcpt12753-cit-0018","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1111\/jcpt.12753-BIB0019|jcpt12753-cit-0019","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"10.1111\/jcpt.12753-BIB0020|jcpt12753-cit-0020","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1007\/s001980070002","article-title":"The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"}],"container-title":["Journal of Clinical Pharmacy and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjcpt.12753","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/jcpt.12753\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T13:03:58Z","timestamp":1671800638000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jcpt.12753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,24]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,2]]}},"URL":"https:\/\/doi.org\/10.1111\/jcpt.12753","archive":["Portico"],"relation":{},"ISSN":["0269-4727"],"issn-type":[{"value":"0269-4727","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,24]]}}}